Get notified when NGNE files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Immediate and Substantial Dilution of $11.43 Per Share (new) — New investors pay $30.00 per share while pro forma net tangible book value per share is $11.43 lower, a steep discount to the offering price.
NASDAQ: NGNE Neurogene Inc. 424B5

Neurogene prices $105M primary offering at $30/share; net proceeds $117.2M with over-allotment

Filed July 2, 2026 · ~1 min read

Key Changes

  • high

    Neurogene is selling 3.5M shares at $30.00 each, plus pre-funded warrants for 666,666 shares at $29.999999, raising about $117.5M before expenses.

    The Offering verify on EDGAR →
  • high

    The company estimates net proceeds of $117.2M (or $134.8M if underwriters' option fully exercised) to fund NGN-401 clinical development, pre-commercial activities, and working capital.

    Use of Proceeds verify on EDGAR →
  • high

    New investors face immediate dilution of $11.43 per share, or $11.13 if the underwriters' option is fully exercised.

    Dilution verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.

Partner

Trade NGNE commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify